¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"serum response factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 2
¿µ¹® serum enzyme ÇÑ±Û Ç÷ûȿ¼Ò
¼³¸í   
  Ç÷û ³»¿¡ Æ÷ÇԵǾî Àִ ¿©·¯ °¡Áö È¿¼Ò¸¦ ÀÏÄ´ ¸»ÀÌ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • immune serum
    ¸é¿ªÇ÷û
  • icteric serum
    Ȳ´ÞÇ÷û
  • inactivated serum
    ºñȰ¼ºÈ­Ç÷û
  • inactive serum
    ºñȰ¼ºÇ÷û
  • lactescent serum
    À¯È­Ç÷û
  • maternal serum screening
    ¸ðüÇ÷û¼±º°°Ë»ç
  • normal serum albumin
    Á¤»óÇ÷û¾ËºÎ¹Î
  • polyvalent serum
    ´Ù°¡Ç÷û
  • pooled serum
    鴂͂֞
  • preimmune serum
    ¸é¿ªÀÌÀüÇ÷û
  • specific serum
    ƯÀÌÇ÷û
  • standard serum
    ±âÁØÇ÷û
  • serum
    Ç÷û
  • serum accident
    Ç÷û»ç°í
  • serum amylase
    Ç÷û¾Æ¹Ð¶ó¾ÆÁ¦
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • factor
    ÀÎÀÚ, ¿äÀÎ, °è¼ö
  • activation factor
    Ȱ¼ºÀÎÀÚ
  • antiplatelet factor
    Ç×Ç÷¼ÒÆÇÀÎÀÚ
  • coagulation V factor
    Á¦5Ç÷¾×ÀÀ°íÀÎÀÚ
  • exclusion of confounding factor
    ±³¶õº¯¼ö¹èÁ¦
  • growth factor
    ¼ºÀåÀÎÀÚ
  • intrinsic factor
    ³»ÀÎÀÎÀÚ, ³»ÀÎÀÚ
  • nerve growth factor
    ½Å°æ¼ºÀåÀÎÀÚ
  • platelet activating factor
    Ç÷¼ÒÆÇȰ¼ºÀÎÀÚ
  • platelet-derived growth factor
    Ç÷¼ÒÆÇÀ¯·¡¼ºÀåÀÎÀÚ, Ç÷¼ÒÆÇ±â¿ø¼ºÀåÀÎÀÚ
  • precipitation factor
    ÃËÁø¿äÀÎ
  • predisposing factor
    ¼±Çà¿äÀÎ
  • prognostic factor
    ¿¹ÈÄÀÎÀÚ
  • psychological factor
    ½É¸®¿ä¼Ò
  • relaxing factor
    ÀÌ¿ÏÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • foreign serum
    ÀÌÁ¾Ç÷û
  • immune human serum globulin
    (¢¡immune globulin) ¸é¿ª±Û·ÎºÒ¸°
  • hyperimmune serum
    °í¸é¿ªÇ÷û
  • serum hepatitis
    Ç÷û°£¿°
  • icteric serum
    Ȳ´ÞÇ÷û
  • immune serum
    ¸é¿ªÇ÷û
  • immune globulin serum
    ¸é¿ªÇ÷û±Û·ÎºÒ¸°
  • inactivated serum
    ºñȰ¼ºÈ­Ç÷û
  • inactive serum
    ºñȰ¼ºÇ÷û
  • serum imbibition
    Ç÷ûÈí¼ö
  • serum intoxication
    Ç÷ûÁßµ¶
  • lactescent serum
    À¯È­Ç÷û
  • polyvalent serum
    ´Ù°¡Ç÷û
  • preimmune serum
    ¸é¿ªÀÌÀüÇ÷û
  • serum rash
    Ç÷û¹ßÁø
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • ideosyncratic drug response
    ƯÀ̼º ¾à¹° ¹ÝÀÀ
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response
    ¸é¿ª¹ÝÀÀ
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response
    ¸é¿ªÀÀ´ä.
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ.
  • immune response gene
    ¸é¿ª¹ÝÀÀÀ¯ÀüÀÚ
  • immune response suppression
    ¸é¿ª¹ÝÀÀ¾ïÁ¦<--¾ï¾Ð>
  • immune response, primary
    ÀÏÂ÷¸é¿ª¹ÝÀÀ
  • immune response, secondary
    ÀÌÂ÷¸é¿ª¹ÝÀÀ
  • immunologic response
    ¸é¿ª¹ÝÀÀ.
  • immunological response
    ¸é¿ªÇÐÀû¹ÝÀÀ
  • inert response
    ºÒȰ¼º ¹ÝÀÀ
  • inspiratory triggering response time
    Èí±âÀ¯¹ß¹ÝÀÀ½Ã°£.
  • placebo response
    Çö󼼺¸¹ÝÀÀ, À§¾à¹ÝÀÀ, ¼ÓÀÓ¾à¹ÝÀÀ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • antitoxic serum
    Ç×µ¶¼Ò(¼º) Ç÷û(¡­úìôè).
  • antitoxic serum
    Ç×µ¶(¼Ò)¼º Ç÷û
  • antitoxic serum
    Ç×µ¶¼Ò(¼º) Ç÷û(¡­úìôè).
  • bovine serum albumin
    ¼Ò Ç÷û¾ËºÎ¹Î
  • convalescent serum
    ȸº¹±âÇ÷û(üÞÜÖÑ¢úìôè).
  • convalescent serum
    ȸº¹±âÇ÷û(üáÜÖÑ¢úìôè)
  • fetal bovine serum
    ¿ìžÆÇ÷û, ¼ÒžÆÇ÷û
  • fetal calf serum
    ¿ìžÆÇ÷û, ¼ÒžÆÇ÷û
  • foreign serum
    ÀÌÁ¾Ç÷û.
  • globulin, immune serum
    ¸é¿ªÇ÷û±Û·ÎºÒ¸°
  • homologous serum jaundice
    µ¿·ùÇ÷û¼º Ȳ´Þ.
  • horse anti serum thymocyte
    ¸¶Ç×Ç÷ûÈä¼±¼¼Æ÷.
  • horse anti serum thymocyte
    ¸»Ç×Ç÷ûÈä¼±¼¼Æ÷.
  • horse serum
    ¸»Ç÷û(?̴̧).
  • horse serum
    ¸»Ç÷û(¡­úìôè).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • whole serum
    ÀüÇ÷û(îïúìôè)
  • adaptive response
    ÀûÀÀÀû ´ëÀÀ(îêëëîÜÓßëë)
  • anamnestic response
    ÀÌÂ÷¸é¿ª¹ÝÀÀ(ì£ó­Øóæ¹Úãëë)
  • anaphylactic response
    ¾Æ³ªÇʶô½Ã½º ´ëÀÀ(Óßëë)
  • antibody response
    Ç×ü ´ëÀÀ(ù÷ô÷Óßëë)
  • autoimmune response
    ÀÚ°¡¸é¿ª´ëÀÀ (í»Ê«Øóæ¹Óßëë)
  • biological response modifier
    »ý¹°ÇÐÀû ´ëÀÀ¼ö½ÄÀÚ(ßæÚªùÊîÜÓßëëáóãÞí­)
  • booster response
    ºÎ½ºÅÍ ´ëÀÀ(Óßëë)
  • dose-response curve
    ¿ë·®´ëÀÀ °î¼±(é»ÕáÓßëëÍØàÊ)
  • heat shock response
    ¿­(æð)
  • immune response
    ¸é¿ª ´ëÀÀ(Øóæ¹Óßëë)
  • immune response gene
    ¸é¿ª ´ëÀÀ À¯ÀüÀÚ(Øóæ¹Óßëëë¶îîí­)
  • lysogenic response
    ¿ë¿ø´ëÀÀ(éÁê«Óßëë)
  • lytic response
    ¿ëÇØ´ëÀÀ(éÁú°Óßëë)
  • memory response
    ±â¾ï´ëÀÀ(ÑÀåãÓßëë)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
EF ectopic focus; edema factor; ejection fraction; elastic fibril; electric field; elongation factor; e...
PF pair feeding; peak flow; perfusion fluid; pericardial fluid; periosteal fibroblast; peritoneal fluid...
HSF heat shock factor; hepatocyte stimulatory factor; histamine sensitizing factor; human serum esterase...
ERA electrical response activity; electroencephalic response audiometry; Electroshock Research Associati...
RR radiation reaction; radiation response; rate ratio; rational recovery [group]; recovery room; relati...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
125I-BSA 125 bovine serum albumin
BSA 125)I-bovine serum albumin
HSA 99m)Tc-human serum albumin
BSA AGE-bovine serum albumin
ALS Anti-lymphocyte serum
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • dose response relationship
    ¹æ»ç¿ë·® ¹ÝÀÀ °ü°è, ¿ë·® ¹ÝÀÀ °ü°è
  • dose-response curve
    ¿ë·® ¹ÝÀÀ °î¼±
  • emotional defense response
    Á¤¼­Àû ¹æ¾î ¹ÝÀÀ
  • ensitization 1. administration of antigen to induce a primary immune response; priming; immunization. 2. exposure to allergen that results in the development of hypersensitivity. 3. the coating of erythrocytes with antibody so that they are subject to lys
    ³»¹ø
    ƯÈ÷ ¾È°Ë ¿¬ÀÇ.
  • evoked response
    À¯¹ß ¹ÝÀÀ
  • humoral immunologic response
    ü¾×¼º ¸é¿ª ¹ÝÀÀ
  • immediate response
    Ãʱ⠹ÝÀÀ
    ¾Ë·¹¸£±â ¹ÝÀÀ°ú °°ÀÌ À¯¹ßÀÎÀÚ¿¡ Á¢ÇÑ ÈÄ, ¸î ÃÊ-¸î ºÐ À̳»¿¡ ÃâÇöÇÏ´Â ¹ÝÀÀ.
  • immune response
    ¸é¿ª ¹ÝÀÀ
  • immunologic response
    ¸é¿ª ¹ÝÀÀ
    Ç׿ø¿¡ ³ëÃâµÊÀ¸·Î½á °³Ã¼ÀÇ ¹ÝÀÀ¼ºÀÌ Æ¯ÀÌÀûÀ¸·Î º¯È­ÇÑ »óÅÂ.
  • learned response
    ÇнÀ ¹ÝÀÀ
    ÇнÀÀ» ½ÃŰ´Â ÀÚ°¡ ÀǵµÇÑ ´ë·Î Çൿ. ¿¹¸¦ µé¸é Á¾ÀÌ ¿ï·Áµµ °³°¡ ħÀ» È긮´Â °ÍÀÌ ÀÖ´Ù.
  • localized protective response
    ±¹¼ÒÀû º¸È£ ¹ÝÀÀ
  • memory immune response
    ¸é¿ªÇÐÀû ±â¾ï ¹ÝÀÀ
  • non-specific response
    ºñƯÀ̼º ¹ÝÀÀ
  • placebo response
    Çö󼼺¸ ¹ÝÀÀ, °¡¾à ¹ÝÀÀ
  • psychophysiologic response
    ½É¸® »ý¸®Àû ¹ÝÀÀ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
response generalisation <biology> The principle that after an organism learns to respond in a particular manner to a stimulus, that stimulus is effective in eliciting similar responses.
(12 Dec 1998)
response hierarchy Alternative reactions or modes of adjustment to a given situation arranged in the probable order of prior effectiveness; e.g., a mother attempting to discipline an unruly child may first request, cajole, then plead, scold, and finally punish; her behaviours can be ordered along a response hierarchy for further monitoring of effectiveness.
(05 Mar 2000)
response rate <oncology> The percentage of patients showing partial or complete response to the given treatment.
(16 Dec 1997)
graft-versus-host response <haematology> A common and serious, complication of bone marrow transplantation where there is a reaction of donated bone marrow against a patient's own tissue.
When donor lymphocytes or a graft containing lymphocytes that are immunologically competent are given to a patient that has low immunological competence, an incompatibility reaction can result. This is due to antibodies from the donor against antigens in the host. This is due to mismatch of MHC Class I antigens and can produce lymphocyte clones that will react by a variety of processes against the host and cause damage.
The clinical condition can be fatal and is due to the donor's immune cells recognising the host cells as foreign.
The clinical entity characterised by anorexia, diarrhoea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the graft-versus-host reaction. It can occur in either chronic or acute forms and is treatable by immunosuppressive drugs.
Seen most commonly following bone marrow transplantation, acute disease is seen after 5-40 days and chronic disease weeks to months after transplantation, affecting, principally, the gastrointestinal tract, liver, and skin.
Radiological appearances of the gastrointestinal tract include; thickened wall, mucosal folds thickened or effaced, increased secretions most likely to be rapid transit of GI tract, mass most likely to be focal oedema, fibrosis, hallmark: diffuse, uniform thickening of small bowel.
Synonym: GVH disease.
Acronym: GVHD
(20 Sep 2002)
complete response <oncology> The disappearance of all clinical evidence of disease. Unfortunately, this does not necessarily mean cure, as microscopic metastases may remain undetected, are likely to regrow and become resistant to treatment.
May also be used in relation to a pathological specimen, where no residual abnormality can be detected in the specimen, in which cas it is referred to as a pathological complete reponse.
Acronym: CR
(16 Mar 1998)
concentration-response curve <pharmacology> This is a graph produced to show the relation between the exposure concentration of a drug (or other chemical) and the degree of response it produces, as measured by the percentage of the exposed population showing a defined, often quantal, effect.
(05 Jan 1998)
conditioned response A response already in an individual's repertoire but which, through repeated pairings with its natural stimulus, has been acquired or conditioned anew to a previously neutral or conditioned stimulus.
See: conditioning.
Compare: unconditioned response.
(05 Mar 2000)
Cushing response A rise in systemic blood pressure when the intracranial pressure acutely increases, usually in excess of 50% of the systolic arterial pressure.
Synonym: Cushing effect, Cushing response.
(05 Mar 2000)
primary antibody response <immunology> Antibodies made upon first exposure to an antigen, mostly of the class IgM.
(05 Mar 1998)
primary immune response <immunology> The immune response to the first challenge by a particular antigen. Usually less extensive than the secondary immune response, being slower and shorter lived with smaller amounts of lower affinity antibody being produced.
(18 Nov 1997)
heat-shock response <cell biology> A constellation of responses that occur when an organism is exposed to excessive heat and other environmental stresses. Responses include synthesis of some proteins, repression of other proteins, and expression of new proteins.
(12 Dec 1998)
heat-shock response element <cell biology, protein> The nucleotide sequence, CNNGAANNTCCNG, which is in the promoter region of the heat-shock genes. When the animal is exposed to certain types of stress such as a sudden rise in temperature, the first thing that happens to activate these genes is the binding of the HSE by a transcriptional enhancer protein.
(09 Oct 1997)
Henry-Gauer response Inhibition of antidiuretic hormone secretion due to a rise in atrial pressure which stimulates atrial stretch receptors.
(05 Mar 2000)
satiety response Behavioural response associated with the achieving of gratification.
(12 Dec 1998)
psychogalvanic response A change in electrical resistance of the skin, occurring in emotion and in certain other conditions.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • uncondltioned response
    ¹«Á¶°Ç¹Ý»ç
  • factor
    ¿ä¼Ò,¿äÀÎ
  • F factor
    FÀÎÀÚ;¿°¼ºÀÎÀÚ
  • R factor
    R ÀÎÀÚ(¼¼±ÕÀÇ ¾àÁ¦ ³»¼º ÀÎÀÚ)
  • Rh factor
    ¸®¼­½º ÀÎÀÚ(ÀûÇ÷±¸ ¼Ó¿¡ ÀÖ´Â ÀÀÇ÷¼Ò)
  • Rhesus factor(antigen)
    =RH FACTOR
  • coal-factor
    ¼®Åº Áß°³ »óÀÎ(µµ¸Å »óÀÎ)
  • common factor
    =COMMON DIVISOR
  • conversion factor
    (¹®ÀÇ.ÀÚ·áû±¸¿¡¼­ ½ÇÁ¦ »óǰ±¸¸ÅÀÎÀ¸·ÎÀÇ)ÀüȯÀ²
  • factor
    ¿ä¼Ò;¿äÀÎ;¿øÀÎ;Àμö;ÀÎÀÚ;°è¼ö;À²;´ë¸®»ó;µµ¸Å»ó;Á߸ÅÀÎ
  • factor analysis
    ÀÎÀÚ ºÐ¼®
  • factor cost
    ¿äÀÎ(¿ä¼­)ºñ¿ë
  • intrinsic factor
    (»ýÈ­)³»À缺ÀÎÀÚ
  • nerve growth factor
    (»ý¸®)½Å°æ ¼ºÀåÀÎÀÚ(Áö°¢(±³°¨)½Å°æ¼¼Æ÷ÀÇ ¼ºÀåÀ» ÀÚ±ØÇÏ´Â ´Ü¹éÁú)
  • noise factor(figure)
    (ÁõÆø±â¿¡¼­ÀÇ)ÀâÀ½Áö¼ö
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á